PE20152004A1 - Inmunoterapia tau - Google Patents
Inmunoterapia tauInfo
- Publication number
- PE20152004A1 PE20152004A1 PE2015001938A PE2015001938A PE20152004A1 PE 20152004 A1 PE20152004 A1 PE 20152004A1 PE 2015001938 A PE2015001938 A PE 2015001938A PE 2015001938 A PE2015001938 A PE 2015001938A PE 20152004 A1 PE20152004 A1 PE 20152004A1
- Authority
- PE
- Peru
- Prior art keywords
- tau
- immunotherapy
- delay
- antibodies against
- symptomatic deterioration
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invencion proporciona anticuerpos contra tau. Los anticuerpos inhiben o retrasan patologias asociadas a tau y deterioro sintomatico asociado
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361780624P | 2013-03-13 | 2013-03-13 | |
US201361800382P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20152004A1 true PE20152004A1 (es) | 2016-02-07 |
Family
ID=51659327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001938A PE20152004A1 (es) | 2013-03-13 | 2014-03-12 | Inmunoterapia tau |
Country Status (20)
Country | Link |
---|---|
US (3) | US10501531B2 (es) |
EP (2) | EP3689904A1 (es) |
JP (2) | JP6674888B2 (es) |
KR (1) | KR102313513B1 (es) |
CN (1) | CN105121465B (es) |
AU (2) | AU2014248515B2 (es) |
BR (1) | BR112015022260B1 (es) |
CA (1) | CA2902026C (es) |
CU (1) | CU24446B1 (es) |
EA (1) | EA035943B1 (es) |
ES (1) | ES2766762T3 (es) |
HK (1) | HK1217337A1 (es) |
IL (1) | IL241124B (es) |
MX (2) | MX2015012225A (es) |
PE (1) | PE20152004A1 (es) |
PH (1) | PH12015501926A1 (es) |
SA (1) | SA515361031B1 (es) |
SG (2) | SG11201506244VA (es) |
WO (1) | WO2014165271A2 (es) |
ZA (1) | ZA201507464B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102494798B1 (ko) | 2012-07-03 | 2023-02-06 | 워싱턴 유니버시티 | Tau에 대한 항체 |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
KR101791296B1 (ko) * | 2014-04-17 | 2017-10-27 | 제주대학교 산학협력단 | 알츠하이머병 관련 돌연변이 유전자를 포함하는 발현 카세트, 벡터, 및 이를 이용하여 형질전환된 세포주 |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
CA2977648C (en) | 2015-02-24 | 2024-01-02 | Rpeptide, Llc | Anti-tau antibodies |
AR103713A1 (es) | 2015-02-26 | 2017-05-31 | Lilly Co Eli | Anticuerpos contra tau y sus usos |
MA41842A (fr) | 2015-03-31 | 2018-02-06 | Oblique Therapeutics Ab | Nouveaux procédés de sélection d'épitope |
TWI827405B (zh) | 2015-06-05 | 2023-12-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
CN107849105B (zh) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | Tau结合抗体 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
CA3022765A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP7481726B2 (ja) * | 2016-05-02 | 2024-05-13 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
JOP20180117B1 (ar) | 2016-07-12 | 2022-03-14 | H Lundbeck As | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها |
MX2019000548A (es) | 2016-07-12 | 2019-10-30 | Revolution Medicines Inc | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2. |
JOP20170154B1 (ar) * | 2016-08-01 | 2023-03-28 | Omeros Corp | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
JP6949102B2 (ja) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | 併用療法 |
JP7193457B2 (ja) | 2016-12-07 | 2022-12-20 | ジェネンテック, インコーポレイテッド | 抗tau抗体及び使用方法 |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
MA47205A (fr) | 2017-01-04 | 2019-11-13 | H Lundbeck As | Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires |
AR110740A1 (es) | 2017-01-23 | 2019-05-02 | Revolution Medicines Inc | Compuestos bicíclicos como inhibidores alostéricos de shp2 |
EP3571189B1 (en) | 2017-01-23 | 2023-03-29 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
MX2019011423A (es) | 2017-03-28 | 2019-11-01 | Genentech Inc | Metodos de tratamiento de enfermedades neurodegenerativas. |
KR20200030029A (ko) * | 2017-05-02 | 2020-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
CA3078565A1 (en) | 2017-10-12 | 2019-04-18 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
JOP20200074A1 (ar) | 2017-10-16 | 2020-04-30 | Eisai R&D Man Co Ltd | أجسام مضادة ضد tau واستخداماتها |
MX2020004338A (es) | 2017-10-25 | 2020-10-14 | Janssen Pharmaceuticals Inc | Composiciones de peptidos tau fosforilados y sus usos. |
MX2020006273A (es) | 2017-12-15 | 2020-09-14 | Revolution Medicines Inc | Compuestos policiclicos como inhibidores alostericos de shp2. |
EP3784274A1 (en) * | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
JP2021530552A (ja) | 2018-07-31 | 2021-11-11 | イーライ リリー アンド カンパニー | 併用療法 |
WO2020163817A1 (en) * | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
TW202100550A (zh) | 2019-03-03 | 2021-01-01 | 愛爾蘭商普羅帝納生物科學公司 | 識別tau之抗體 |
CA3148740A1 (en) | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
IL298215A (en) | 2020-05-19 | 2023-01-01 | Othair Prothena Ltd | A multi-epitope vaccine for the treatment of Alzheimer's disease |
CN113254929B (zh) * | 2021-05-21 | 2023-11-07 | 昆山翦统智能科技有限公司 | 一种企业远程智能服务的免疫计算与决策方法及*** |
TW202328177A (zh) | 2021-08-27 | 2023-07-16 | 美商建南德克公司 | 治療tau病理學之方法 |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
WO2023178049A1 (en) | 2022-03-14 | 2023-09-21 | Genentech, Inc. | Predicting neurodegenerative diseases based on speech analyses |
WO2023250326A1 (en) | 2022-06-21 | 2023-12-28 | Genentech, Inc. | Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses |
Family Cites Families (159)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH652145A5 (de) | 1982-01-22 | 1985-10-31 | Sandoz Ag | Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen. |
US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DE69330523T4 (de) | 1992-08-21 | 2012-08-23 | Vrije Universiteit Brussel | Immunoglobuline ohne leichte ketten |
AU6014094A (en) | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
DK0673418T3 (da) | 1992-12-14 | 1999-03-01 | Innogenetics Nv | Monoklonale antistoffer rettet mod mikrotubulusassocieret tau-protein, hybridomaer, der secernerer disse antistoffer, antig |
ATE415173T1 (de) | 1993-09-14 | 2008-12-15 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
JP5087758B2 (ja) | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | アジュバントとして非メチル化CpGジヌクレオチドを含む核酸の使用 |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
ATE371231T1 (de) | 1999-02-05 | 2007-09-15 | Samsung Electronics Co Ltd | Verfahren und vorrichtung zur wiederauffindung von texturbildern |
AT500379B8 (de) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | Tau-proteine |
MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
AU2003257850A1 (en) | 2002-08-14 | 2004-03-03 | Mitsubishi Kagaku Iatron, Inc. | ANTIBODY SPECIFIC TO CENTRAL Tau-PROTEIN |
BR0316525A (pt) | 2002-11-29 | 2005-10-04 | Boehringer Ingelheim Pharma | Genes de fosfotransferase de neomicina e processos para seleção de células recombinantes de alta produtividade |
US7847146B2 (en) * | 2003-03-28 | 2010-12-07 | Baylor College Of Medicine | Model for neurodegenerative disorders |
DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
US20050132424A1 (en) * | 2003-10-21 | 2005-06-16 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing Abeta42-Dutch |
AU2005291486A1 (en) | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
JP4620739B2 (ja) | 2004-11-10 | 2011-01-26 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Cho細胞に対する細胞保存戦略を最適化するためのフローサイトメトリ分析の使用 |
WO2006067122A2 (en) | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing west nile virus and uses thereof |
CA2593693A1 (en) | 2004-12-30 | 2006-07-13 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Framework residue substituted humanized col-1 antibodies and their use |
JP2009506790A (ja) * | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | 毒素とコンジュゲートしたeph受容体抗体 |
US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
KR20090019864A (ko) * | 2006-06-16 | 2009-02-25 | 엔비보 파마슈티칼즈, 인코퍼레이티드 | Tau와 아밀로이드 전구체 단편을 발현하는 유전자도입 파리 |
CA2655379A1 (en) * | 2006-06-22 | 2007-12-27 | Walter And Eliza Hall Institute Of Medical Research | Structure of the insulin receptor ectodomain |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
WO2008022153A2 (en) * | 2006-08-14 | 2008-02-21 | The Regents Of The University Of California | Inhibitors of pde4 and methods of use |
TWI447124B (zh) * | 2006-12-01 | 2014-08-01 | Medarex Llc | 結合cd22的人類抗體與其應用 |
EP2118300B1 (en) | 2007-02-23 | 2015-05-27 | Prothena Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TWI419902B (zh) | 2007-03-02 | 2013-12-21 | 百靈佳殷格翰製藥公司 | 蛋白質產製之改良 |
EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
JP2009056790A (ja) | 2007-09-03 | 2009-03-19 | Takao Otogawa | ファイル用ポケット |
JP5685442B2 (ja) * | 2007-09-26 | 2015-03-18 | ウー3・フアルマ・ゲー・エム・ベー・ハーU3 Pharma | ヘパリン結合上皮成長因子様成長因子抗原結合タンパク質 |
US9272030B2 (en) | 2007-10-17 | 2016-03-01 | Janssen Sciences Ireland Uc | Use of tau to monitor immunotherapy |
JP5745854B2 (ja) * | 2007-11-13 | 2015-07-08 | テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド | Tl1aに対するヒト化抗体 |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
JP2010014691A (ja) * | 2008-06-20 | 2010-01-21 | Igaku Seibutsugaku Kenkyusho:Kk | 腹水中のメソテリン及び/又は巨核球増強因子を検出するための方法、キット、試薬及び装置 |
RU2547595C2 (ru) | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Антитела против ccr2 |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
TWI614267B (zh) | 2009-05-13 | 2018-02-11 | 建新公司 | 抗人類cd52免疫球蛋白 |
EP2440234A4 (en) * | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
US20110045534A1 (en) * | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
WO2011026031A1 (en) | 2009-08-28 | 2011-03-03 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
WO2011053565A2 (en) | 2009-10-29 | 2011-05-05 | Biomedical Sciences Research Centre "Alexander Fleming" | Compositions and methods for detecting a tauopathy |
WO2011075636A2 (en) | 2009-12-18 | 2011-06-23 | Amgen Inc. | Wise binding agents and epitopes |
US8945576B2 (en) | 2010-01-08 | 2015-02-03 | Kyoto University | Vaccine for treatment of tautopathy |
CN102985113B (zh) | 2010-02-23 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 用于肿瘤诊断和治疗的组合物和方法 |
WO2011130377A2 (en) | 2010-04-15 | 2011-10-20 | Abbott Laboratories | Amyloid-beta binding proteins |
ITRM20100320A1 (it) * | 2010-06-11 | 2011-12-11 | Consiglio Nazionale Ricerche | Metodo per la diagnostica e il trattamento delle taupatie |
US20120023911A1 (en) | 2010-07-28 | 2012-02-02 | Gm Global Technology Operations, Inc. | Detection of exhaust particulate filter substrate failure |
NZ609984A (en) * | 2010-10-11 | 2015-05-29 | Biogen Idec Internat Neuroscience Gmbh | Human anti-tau antibodies |
AR084210A1 (es) * | 2010-12-08 | 2013-05-02 | Abbott Lab | PROTEINAS DE UNION AL TNF-a |
WO2012109280A2 (en) * | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
US8697076B2 (en) | 2011-04-27 | 2014-04-15 | Northwestern University | Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies |
GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
GB201111361D0 (en) * | 2011-07-04 | 2011-08-17 | Nordic Bioscience As | Biochemical markers for neurodegenerative conditions |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
AU2012298877B2 (en) * | 2011-08-22 | 2018-01-04 | Emergent Biosolutions Canada Inc. | Clostridium difficile antibodies |
SG10201912955PA (en) | 2011-09-19 | 2020-02-27 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
CA2850686C (en) | 2011-10-07 | 2020-09-08 | Ac Immune S.A. | Phosphospecific antibodies recognising tau |
TWI605060B (zh) | 2012-03-28 | 2017-11-11 | 賽諾菲公司 | 抗緩激肽b1受體配位體之抗體 |
WO2013151762A1 (en) | 2012-04-05 | 2013-10-10 | Ac Immune S.A. | Humanized tau antibody |
US9428864B2 (en) | 2012-04-18 | 2016-08-30 | E I Du Pont De Nemours And Company | Multilayered sheet |
DE102012211455A1 (de) | 2012-07-02 | 2014-01-02 | Wobben Properties Gmbh | Handhabungsvorrichtung zum Handhaben einer Rotorblattform zum Fertigen eines Rotorblattes einer Windenergieanlage |
KR102494798B1 (ko) * | 2012-07-03 | 2023-02-06 | 워싱턴 유니버시티 | Tau에 대한 항체 |
WO2014028777A2 (en) | 2012-08-16 | 2014-02-20 | Ipierian, Inc. | Methods of treating a tauopathy |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
US9650436B2 (en) | 2012-10-12 | 2017-05-16 | Arizona Board Of Regents On Behalf Of Arizona State University | Antibody based reagents that specifically recognize toxic oligomeric forms of tau |
US9200068B2 (en) | 2012-12-18 | 2015-12-01 | Regents Of The University Of Minnesota | Compositions and methods related to tauopathy |
EP3792278A3 (en) | 2012-12-21 | 2021-05-26 | Biogen MA Inc. | Human anti-tau antibodies |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
US9364191B2 (en) | 2013-02-11 | 2016-06-14 | University Of Rochester | Method and apparatus of spectral differential phase-contrast cone-beam CT and hybrid cone-beam CT |
AU2014248515B2 (en) | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
CA2903091C (en) | 2013-03-15 | 2022-09-06 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
WO2014152773A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of The University Of Pennsylvania | Blood biomarkers that predict persistent cognitive dysfunction after concussion |
WO2015027082A1 (en) | 2013-08-22 | 2015-02-26 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
CN111569063A (zh) | 2013-11-27 | 2020-08-25 | 伊皮埃里安股份有限公司 | 治疗tau病变的方法 |
CN106030310B (zh) | 2013-12-13 | 2019-01-04 | 通用医疗公司 | 可溶性高分子量(hmw)tau种类及其应用 |
PT3083689T (pt) * | 2013-12-17 | 2020-08-27 | Genentech Inc | Anticorpos anti-cd3 e métodos de utilização |
US9629801B2 (en) | 2014-01-10 | 2017-04-25 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
US20150253341A1 (en) | 2014-02-10 | 2015-09-10 | Merck Sharp & Dohme Corp. | Quantification of tau in biological samples by immunoaffinity enrichment and mass spectrometry |
JP2017521063A (ja) | 2014-06-26 | 2017-08-03 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 微小管結合タンパク質タウに特異的に結合する抗体及び抗原結合断片 |
TWI664190B (zh) | 2014-06-27 | 2019-07-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
PL3221349T3 (pl) | 2014-11-19 | 2021-05-17 | Axon Neuroscience Se | Humanizowane przeciwciała tau w chorobie Alzheimera |
CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
CA2977648C (en) | 2015-02-24 | 2024-01-02 | Rpeptide, Llc | Anti-tau antibodies |
TWI827405B (zh) | 2015-06-05 | 2023-12-21 | 美商建南德克公司 | 抗-tau抗體及使用方法 |
US20200030445A1 (en) | 2015-06-12 | 2020-01-30 | C2N Diagnostics, Llc | Stable formulations of humanized anti-tau antibody |
CN107849105B (zh) | 2015-07-06 | 2021-09-17 | Ucb生物制药有限责任公司 | Tau结合抗体 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
EP3325506A1 (en) | 2015-07-21 | 2018-05-30 | BioArctic AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
CA2997960A1 (en) | 2015-10-06 | 2017-04-13 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
ES2933491T3 (es) | 2016-05-02 | 2023-02-09 | Prothena Biosciences Ltd | Inmunoterapia tau |
CA3022765A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
JP7481726B2 (ja) | 2016-05-02 | 2024-05-13 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
WO2018085653A1 (en) | 2016-11-04 | 2018-05-11 | The Regents Of The University Of California | Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them |
JP7193457B2 (ja) | 2016-12-07 | 2022-12-20 | ジェネンテック, インコーポレイテッド | 抗tau抗体及び使用方法 |
CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
MA47499A (fr) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc | Anticorps anti-tau et leurs procédés d'utilisation |
EP3585430A4 (en) | 2017-02-21 | 2020-12-09 | REMD Biotherapeutics, Inc. | TREATMENT OF CANCER WITH ANTIBODIES THAT BIND TO T-CYTOTOXIC T-LYMPHOCYTES ANTIGEN-4 (CTLA-4) |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
MX2019011423A (es) | 2017-03-28 | 2019-11-01 | Genentech Inc | Metodos de tratamiento de enfermedades neurodegenerativas. |
US11028157B2 (en) | 2017-03-28 | 2021-06-08 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
KR20200030029A (ko) | 2017-05-02 | 2020-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
KR20200018502A (ko) | 2017-06-16 | 2020-02-19 | 브리스톨-마이어스 스큅 컴퍼니 | 타우병증 치료를 위한 조성물 및 방법 |
JOP20200074A1 (ar) | 2017-10-16 | 2020-04-30 | Eisai R&D Man Co Ltd | أجسام مضادة ضد tau واستخداماتها |
CN111587123A (zh) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
US20200369754A1 (en) | 2017-12-04 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Binding molecules that specifically bind to tau |
WO2019180261A1 (en) | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
CA3095443A1 (en) | 2018-03-28 | 2019-10-03 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
WO2020097561A1 (en) | 2018-11-08 | 2020-05-14 | Prothena Biosciences Limited | Antibodies recognizing tau |
WO2020096608A1 (en) | 2018-11-08 | 2020-05-14 | Prothena Biosciences Limited | Antibodies recognizing tau |
CN113490505A (zh) | 2018-11-19 | 2021-10-08 | 德克萨斯大学***董事会 | 用于治疗tau蛋白病的tau肽抗原及与其结合的抗体 |
WO2020163817A1 (en) | 2019-02-08 | 2020-08-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
TW202100550A (zh) | 2019-03-03 | 2021-01-01 | 愛爾蘭商普羅帝納生物科學公司 | 識別tau之抗體 |
CN113631573B (zh) | 2019-03-25 | 2024-06-04 | 国家医疗保健研究所 | 抗Tau抗体及其在制备用于治疗疾病的药物中的用途 |
CA3143811A1 (en) | 2019-07-15 | 2021-01-21 | Seung-Yong Yoon | Anti-tau antibody and use of same |
-
2014
- 2014-03-12 AU AU2014248515A patent/AU2014248515B2/en active Active
- 2014-03-12 MX MX2015012225A patent/MX2015012225A/es active IP Right Grant
- 2014-03-12 ES ES14778358T patent/ES2766762T3/es active Active
- 2014-03-12 US US14/776,724 patent/US10501531B2/en active Active
- 2014-03-12 PE PE2015001938A patent/PE20152004A1/es not_active Application Discontinuation
- 2014-03-12 WO PCT/US2014/025044 patent/WO2014165271A2/en active Application Filing
- 2014-03-12 SG SG11201506244VA patent/SG11201506244VA/en unknown
- 2014-03-12 JP JP2016501731A patent/JP6674888B2/ja active Active
- 2014-03-12 CA CA2902026A patent/CA2902026C/en active Active
- 2014-03-12 KR KR1020157025094A patent/KR102313513B1/ko active IP Right Grant
- 2014-03-12 EP EP19213368.4A patent/EP3689904A1/en active Pending
- 2014-03-12 CU CU2015000117A patent/CU24446B1/es unknown
- 2014-03-12 EA EA201591285A patent/EA035943B1/ru unknown
- 2014-03-12 CN CN201480014601.6A patent/CN105121465B/zh active Active
- 2014-03-12 SG SG10201707855YA patent/SG10201707855YA/en unknown
- 2014-03-12 BR BR112015022260-9A patent/BR112015022260B1/pt active IP Right Grant
- 2014-03-12 EP EP14778358.3A patent/EP2970453B1/en active Active
-
2015
- 2015-09-01 PH PH12015501926A patent/PH12015501926A1/en unknown
- 2015-09-03 IL IL241124A patent/IL241124B/en active IP Right Grant
- 2015-09-10 SA SA515361031A patent/SA515361031B1/ar unknown
- 2015-09-10 MX MX2020010040A patent/MX2020010040A/es unknown
- 2015-10-08 ZA ZA2015/07464A patent/ZA201507464B/en unknown
-
2016
- 2016-05-09 HK HK16105255.1A patent/HK1217337A1/zh unknown
-
2019
- 2019-06-06 AU AU2019203976A patent/AU2019203976B2/en active Active
- 2019-10-29 US US16/667,647 patent/US11643457B2/en active Active
-
2020
- 2020-03-09 JP JP2020039557A patent/JP7044399B2/ja active Active
-
2023
- 2023-04-21 US US18/305,109 patent/US20230340094A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20152004A1 (es) | Inmunoterapia tau | |
CY1122398T1 (el) | Συνδυαστικες θεραπειες με αντισωματα anti-cd38 | |
JP1640198S (ja) | イヤホンケース | |
DK3735147T3 (da) | Rygsæk | |
IT201700062337A1 (it) | Occhiali con dispositivi auricolari | |
DK3577219T3 (da) | Alfa-amylase-varianter | |
DK3557162T3 (da) | Køleskab | |
UA38793S (uk) | Акумуляторна батарея | |
DK3893519T3 (da) | Modtager | |
IT201700105376A1 (it) | Compressore alternativo | |
ES1198108Y (es) | Estuche pintalbios con mechero | |
ES1199235Y (es) | Retel con microcámara | |
UA40471S (uk) | Рюкзак | |
UA39801S (uk) | Рюкзак | |
UA39804S (uk) | Рюкзак | |
UA39712S (uk) | Рюкзак | |
UA39805S (uk) | Рюкзак | |
UA39803S (uk) | Рюкзак | |
UA39802S (uk) | Рюкзак | |
UA39713S (uk) | Рюкзак | |
UA39435S (uk) | Кейс | |
UA39296S (uk) | Кейс | |
UA39294S (uk) | Кейс | |
UA39155S (uk) | Кейс | |
UA38873S (uk) | Рюкзак |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |